Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EWTX vs SYRE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EWTX Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 2–4 Matrix Metrics)

EWTX Overall Winner 6-Pillar Tally: EWTX 4 – 0 SYRE (2 Tie) Matrix Metrics: EWTX 2 – 4 SYRE

As of Nov 16, 2026, Edgewise Therapeutics, Inc. (EWTX) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 2–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EWTX carries a Unified Composite Score of 35.4/100 (SELL) at $43.61 (N/M Forward P/E, 0.0% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While SYRE currently prints a higher short-term Unified Composite Score (44.4/100 HOLD vs. EWTX 35.4/100 SELL), EWTX captures the overall institutional head-to-head verdict (2–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EWTX vs SYRE
EWTX NASDAQ Head-to-Head Winner
Edgewise Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$43.61
-5.05% 1D
Market Cap $5.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.19β · 74% Vol
Unified Composite Score
35.4 / 100 SELL
Tech 15.0 Fund 37.0 Flow 66.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.3 · SMA20: $41.56 · SMA50: $41.34
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.5 · SMA20: $98.78 · SMA50: $91.70

6-Pillar Scorecard Institutional Category Breakdown (EWTX 4 – 0 SYRE)

Columns: Metric · EWTX · SYRE
1. Valuation Multiples EWTX
Forward P/E N/M N/M
Trailing P/E 5.5x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% -99.7%
TTM Revenue (USD) N/A N/A
Market Cap $5.0B $9.8B
3. Profitability & Quality EWTX
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) 92.1% -35.0%
4. Balance Sheet & Cash Flow EWTX
Cash Generation (TTM) -$202M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $65M Net Cash $10.06 Book/Sh · -35.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EWTX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 133.7% (17th %ile) 87.9% (10th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EWTX (2) vs SYRE (4)
Institutional Metric EWTX SYRE Criterion Row Edge
Market Capitalization
Scale
$5.0B $9.8B Larger Scale SYRE
Trailing P/E Ratio
Valuation
5.5x N/M Lower Multiple EWTX
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
92.1% -35.0% Higher ROE EWTX
52-Week Range Position
Momentum
82% ($20–$49) 88% ($22–$111) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
1.19β · 74% Vol 1.75β · 59% Vol Lower Realized Risk SYRE
Unified Institutional Score
Composite Signal
35.4 / 100 (SELL) 44.4 / 100 (HOLD) Higher Composite SYRE
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$202M ($65M Net Cash) N/A ($10.06 Book/Sh · -35.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +7.85 pp
EWTX: +17.26% · SYRE: +25.11%
3M Horizon EWTX +6.16 pp
EWTX: -1.13% · SYRE: -7.29%
6M Horizon SYRE +5.16 pp
EWTX: +37.48% · SYRE: +42.64%
1Y Horizon SYRE +228.17 pp
EWTX: +113.57% · SYRE: +341.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EWTX vs SYRE. Trailing 12-month operating profitability (EWTX 0.0% vs SYRE 0.0%) and valuation multiples (EWTX N/M vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EWTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E92.1% · N/M
SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EWTX CONSOLIDATION
91d in phase · OBV ACCUMULATION
Current IV 133.7%
IV Percentile 17th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EWTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EWTX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $5.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EWTX vs SYRE Key Questions & Quantitative Answers

As of Nov 16, 2026, Edgewise Therapeutics, Inc. (EWTX) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 2–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EWTX carries a Unified Composite Score of 35.4/100 (SELL) at $43.61 (N/M Forward P/E, 0.0% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While SYRE currently prints a higher short-term Unified Composite Score (44.4/100 HOLD vs. EWTX 35.4/100 SELL), EWTX captures the overall institutional head-to-head verdict (2–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).

EWTX and SYRE split Growth & Scale metrics: EWTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SYRE at +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, EWTX generates N/A in USD-normalized revenue versus N/A for SYRE. In operating R&D and SG&A reinvestment, EWTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SYRE.

EWTX screens cheaper on headline valuation multiples. EWTX trades at N/M Forward P/E, 5.5x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EWTX (92.1% ROE) versus SYRE (-35.0% ROE) capital efficiency.

In options market volatility and institutional positioning, EWTX carries 133.7% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.19β · 74% Vol realized risk). By comparison, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.